Persistent anti-Dra in two pregnancies

Publications

Share / Export Citation / Email / Print / Text size:

Immunohematology

American National Red Cross

Subject: Medical Laboratory Technology

GET ALERTS SUBSCRIBE

ISSN: 0894-203X
eISSN: 1930-3955

DESCRIPTION

4
Reader(s)
4
Visit(s)
0
Comment(s)
0
Share(s)

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue / page

Archive
Volume 37 (2021)
Volume 36 (2020)
Volume 35 (2019)
Volume 34 (2018)
Volume 33 (2017)
Volume 32 (2016)
Volume 31 (2015)
Volume 30 (2014)
Volume 29 (2013)
Volume 28 (2012)
Volume 27 (2011)
Volume 26 (2010)
Volume 25 (2009)
Volume 24 (2008)
Volume 23 (2007)
Volume 22 (2006)
Volume 21 (2005)
Volume 20 (2004)
Volume 19 (2003)
Volume 18 (2002)
Volume 17 (2001)
Volume 16 (2000)
Volume 15 (1999)
Volume 14 (1998)
Volume 13 (1997)
Volume 12 (1996)
Volume 11 (1995)
Volume 10 (1994)
Volume 9 (1993)
Volume 8 (1992)
Volume 7 (1991)
Volume 6 (1990)
Volume 5 (1989)
Volume 4 (1988)
Volume 3 (1987)
Related articles

VOLUME 21 , ISSUE 3 (September 2005) > List of articles

Persistent anti-Dra in two pregnancies

Naomi Rahimi-Levene / Abraham Kornberg / Gabriela Siegel / Valery Morozov / Eilat Shinar / Orna Asher / Cyril Levene / Vered Yahalom

Keywords : Anti-Dra, titers in pregnancy

Citation Information : Immunohematology. Volume 21, Issue 3, Pages 126-128, DOI: https://doi.org/10.21307/immunohematology-2019-405

License : (Transfer of Copyright)

Published Online: 28-April-2020

ARTICLE

ABSTRACT

The Drori (Dra) antigen is one of the ten high-prevalence antigens of the Cromer blood system, which are carried on decayaccelerating factor (DAF, CD55). The Dr(a–) phenotype was first described in a 48-year-old Jewish woman from Bukhara. Her serum contained an antibody to a high-prevalence antigen named anti-Dra. Most known individuals with the Dr(a–) phenotype are Jews from the geographic area of Bukhara, but individuals from Japan have also been described. Antibodies in the Cromer blood group system, including anti-Dra, have never been reported to cause HDN. In most of the cases with anti-Dra examined in Israel, the antibodies have been subtyped as IgG2 and IgG4. This report is of a woman with Dr(a–) phenotype and an anti-Dra titer of 256 to 512 in her serum, observed during two successive pregnancies. At birth, the RBCs of the first- and second-born child were negative and positive in the DAT, respectively, and neither manifested clinical signs of HDN. The disappearance of Cromer system antibodies, including anti-Dra in midpregnancy, has been described in a previous study. In that study, it was theorized that the antibodies in the serum of the women were adsorbed onto placental DAF. The finding of a high anti-Dra titer in two successive pregnancies in this patient, with a positive DAT for the RBCs of one of the two babies at term,differs from published reports, suggesting that a different mechanism might be involved.

You don't have 'Full Text' access of this article.

Purchase Article Subscribe Journal Share